Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE